ESMO 2017: CDK 4/6 inhibitors from a patient’s perspective

Professor Kimberley Blackwell (Duke University, North Carolina, USA) chairs an expert discussion on the latest in CDK inhibition in breast cancer and what this means for patients for ecancer at ESMO 2017 in Madrid. Professor Blackwell is joined by Dr...

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2wPqmMV
via IFTTT